Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma Highlights Opportunity for EXXUATM as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Aytu BioPharma Announces Commercial Availability of EXXUA Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
Standard Uranium Provides Drilling Update on the 2026 Drill Program at Flagship Davidson River Project - Announces Elevated Radioactivity in First Drill Hole
Goldgroup Closes Purchase of the San Francisco Gold Mine Acquiring 100% of Molimentales Del Noroeste, S.A. de C.V.
Bold Ventures Commences Summer Fieldwork at Burchell, Follows up at 111 Zone and JET Rare Earth Element System
